Intuitive Surgical sits at multi-year-low forward valuations, at times below its 2022 trough and late-2010s lows over the last six quarters, though cheap can get cheaper, as it did after earnings. The concern with higher-cost exposure is China, not competition from J&J's Ottava or Medtronic's Hugo. The stock is tricky to read through sector correlation because it straddles medical devices, the Nasdaq 100 and momentum. x.com 

TransMedics still trades cheap against sector averages given its 20%+ growth, after the market overpunished its investment-heavy focus. Q3 numbers are very likely to impress with a strong growth acceleration, and since the market focuses on the short term, the stock should keep climbing in the coming months. Medtech has suffered without much justification as funds rotated into now-richer biotech, and capital should flow back over the next few years, lifting valuations after five negative years. … Show more

Johnson & Johnson is not the S&P 500 laggard its five-year sideways chart suggests once dividends and longer timelines are counted: over 20 years it trails the index by only the tiniest amount. That says something for a very low-beta stock with one of only two AAA credit ratings, alongside Microsoft. It is a strong anchor for when momentum and growth stocks get clobbered. x.com  x.com  x.com 

Johnson & Johnson looks expensive at 22x for its growth, even though its story is clean. Limited loss-of-exclusivity risk until the 2030s, a cleanup via spin-off and divestments, and a pipeline in IBS and cancer could deliver double-digit EPS growth before 2030, and Street estimates are probably too low. Still, Stryker at about 20x 2027 earnings, with high-single-digit organic growth and strong M&A skills, beats JNJ at 21x, which tends to overpay for growth like typical large pharma. x.com 

Boston Scientific's H2 2027 heart-device launches could revive growth in 2028, lifting earnings and its valuation multiple. Slowing heart-treatment growth led to a guidance cut, though Q2 organic sales grew 7% and adjusted EPS about 15%. August's cyberattack later disrupted operations, which have recovered. The potential opportunity requires patience: management expects minimal EPS growth in 2027, and competition could keep growth subdued after the launches. x.com 

Boston Scientific and Abbott are cheaper than their history but unlikely to compound at 20% over the next five years. The medical-device selloff looks like a clear overreaction, but Intuitive Surgical is worth paying up for even after a 30% drawdown, and TransMedics and PROCEPT BioRobotics have a real shot at about 30% annual returns over five years on 20%-plus revenue growth, operating leverage and possible multiple expansion. Favoring growth over cheaper names means more risk but more upside. … Show more

Boston Scientific looks cheap on an estimate-based cash-earnings screen: 13x current and 12x next year's cash earnings versus 14x for medical-device makers imply a $43.85-$55.81 fair range against $42.04. This is a levels-only comparison using reported estimates, not fundamental diligence. x.com 

Johnson & Johnson's valuation does not make sense at a premium to Thermo Fisher and roughly flat to Danaher. @PythiaR, replying, calls J&J a clean story with limited patent-loss risk until the 2030s and a strong pipeline, but expensive at 22x, and prefers medtech such as Stryker. Pharma may simply have been easier to own than medtech given OBBB payer eligibility changes and hospital procedure volume risk, while life sciences has disappointed. x.com 

Boston Scientific warrants caution because its debt levels leave it behind much cleaner, higher-quality medical-device stories. x.com 

High-quality healthcare companies such as Thermo Fisher, Boston Scientific, Novo Nordisk and Abbott now trade at washed-out multiples, which may make the space one of the cheapest pockets of the market on a quality-adjusted basis while SaaS draws the attention. x.com